{
    "id": "dbpedia_96_3",
    "rank": 20,
    "data": {
        "url": "https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c00268",
        "read_more_link": "",
        "language": "en",
        "title": "In Silico Assisted Identification, Synthesis, and In Vitro Pharmacological Characterization of Potent and Selective Blockers of the Epilepsy-Associated KCNT1 Channel",
        "top_image": "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/acs.jmedchem.4c00268.social.jpeg_v03",
        "meta_img": "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/acs.jmedchem.4c00268.social.jpeg_v03",
        "images": [
            "https://pubs.acs.org/pb-assets/ux3/pubs-logo-481x82-1523435513963.png",
            "https://pubs.acs.org/cms/10.1021/jmcmar/asset/16ad6e14-a616-d6e1-ba61-ad6e14ba616a/title.png",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/loading/loading-018624cffd023ad5641b8e99931a80e6.gif",
            "https://pubs.acs.org/doi/10.1021/specs/products/achs/releasedAssets/images/loading/loader-128b5db1cc3a83761a15cf2e5c9b452d.gif",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/access-control/open-access.svg",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/cc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/by.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nd.svg",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0015.gif",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/cc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/by.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nd.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/cc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/cc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/by.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nd.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/by.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/cc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/by.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nd.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/cc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/by.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nd.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nd.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/cc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/by.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nd.svg",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0001.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0010.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0011.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0012.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0013.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0014.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0002.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0003.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0004.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0005.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0006.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0007.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0008.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0009.gif",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/products/achs/releasedAssets/images/orchid-2856f829046fbda55b90e1582edf0e9a.png",
            "https://pubs.acs.org/cms/10.1021/jmcmar.2024.67.issue-11/asset/1910c77e-3419-0c77-e341-10c77ee34191/jmcmar.2024.67.issue-11.largecover.jpg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/cc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/by.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nc.svg",
            "https://pubs.acs.org/specs/products/achs/releasedAssets/images/cc-license/nd.svg",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0015.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0001.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0010.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0011.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0012.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0013.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0014.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0002.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0003.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0004.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0005.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0006.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0007.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0008.gif",
            "https://pubs.acs.org/cms/10.1021/acs.jmedchem.4c00268/asset/images/medium/jm4c00268_0009.gif",
            "https://pubs.acs.org/pb-assets/images/footer_logos/logo-atypon-1525376610217.png",
            "https://pubs.acs.org/pb-assets/images/footer_logos/logo-chorus-1525375622947.png",
            "https://pubs.acs.org/pb-assets/images/footer_logos/logo-cope-1525375622977.png",
            "https://pubs.acs.org/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg",
            "https://pubs.acs.org/pb-assets/images/footer_logos/logo-crossref-1525377362093.png",
            "https://pubs.acs.org/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png",
            "https://pubs.acs.org/pb-assets/images/footer_logos/logo-orcid-1525375623187.png",
            "https://pubs.acs.org/pb-assets/images/footer_logos/logo-portico-1525375623203.png",
            "https://pubs.acs.org/pb-assets/ux3/ACSPubs_logo_tagline_Knockout-1718648850557.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Rita Turcio",
            "Deborah Puzo",
            "Giacomo Pepe",
            "Isabel Gomez-Monterrey",
            "Maria Virginia Soldovieri",
            "Veronica Di Sarno",
            "Pietro Campiglia",
            "Francesco Miceli",
            "Alessia Bertamino",
            "Carmine Ostacolo"
        ],
        "publish_date": "2024-05-23T00:00:00",
        "summary": "",
        "meta_description": "Gain-of-function (GoF) variants in KCNT1 channels cause severe, drug-resistant forms of epilepsy. Quinidine is a known KCNT1 blocker, but its clinical use is limited due to severe drawbacks. To identify novel KCNT1 blockers, a homology model of human KCNT1 was built and used to screen an in-house library of compounds. Among the 20 molecules selected, five (CPK4, 13, 16, 18, and 20) showed strong KCNT1-blocking ability in an in vitro fluorescence-based assay. Patch-clamp experiments confirmed a higher KCNT1-blocking potency of these compounds when compared to quinidine, and their selectivity for KCNT1 over hERG and Kv7.2 channels. Among identified molecules, CPK20 displayed the highest metabolic stability; this compound also blocked KCNT2 currents, although with a lower potency, and counteracted GoF effects prompted by 2 recurrent epilepsy-causing KCNT1 variants (G288S and A934T). The present results provide solid rational basis for future design of novel compounds to counteract KCNT1-related neurological disorders.",
        "meta_lang": "en",
        "meta_favicon": "/pb-assets/ux3/favicon-1635812676023.ico",
        "meta_site_name": "ACS Publications",
        "canonical_link": "https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c00268",
        "text": "Special Issue\n\nPublished as part of Journal of Medicinal Chemistry virtual special issue “Many Faces of Medicinal Chemistry”.\n\nThe Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c00268.\n\nChemical structures and characterizing chemical-physical parameters of the tested molecules (Table S1); NMR and CD spectra of the newly synthesized compounds (Figures S1–S22); HPLC traces of all of the tested compounds (Figures S23–S42); docking poses of CPK4 (A), CPK13 (B), CPK16 (C), CPK18 (D), CPK20 (E) and quinidine (F) on HMhKCNT198–354 (Figure S43); ligand interaction diagrams of CPK4 (A), CPK13 (B), CPK16 (C), CPK18 (D), CPK20 (E) and quinidine (F) in complex with HMhKCNT198–354 (Figures S44); method validation parameters for LC/MS quantitation of test compounds (Table S2); functional and pharmacological properties of KCNT1 F346S channels (Figure S45); pharmacological characterization of selected CPK compounds on KCNT1 or KCNT1 F346S channels (Figure S46); representative graph showing the linear regression of the natural logarithm of % remaining parent compounds CPK19 and CPK20 (Figure S47); compound CPK18 metabolic fate as determined by LC analysis (Figure S48); molecular structures of compound CPK18 main oxidized metabolites as determined by LC-MS/MS analysis (Figure S49); molecular structures of compound CPK18 main glucuronic metabolites as determined by LC-MS/MS analysis (Figure S50) (PDF)\n\nMolecular formula strings (CSV)\n\nEMhKCNT1_CPK4 (PDB)\n\nEMhKCNT1_CPK13 (PDB)\n\nEMhKCNT1_CPK16 (PDB)\n\nEMhKCNT1_CPK18 (PDB)\n\nEMhKCNT1_CPK20 (PDB)\n\nEMhKCNT1_QND_pose1 (PDB)\n\nEMhKCNT1_QND_pose2 (PDB)\n\nHMhKCNT1_CPK4 (PDB)\n\nHMhKCNT1_CPK13 (PDB)\n\nHMhKCNT1_CPK16 (PDB)\n\nHMhKCNT1_CPK18 (PDB)\n\nHMhKCNT1_CPK20 (PDB)\n\nHMhKCNT1_QND (PDB)\n\nTerms & Conditions\n\nMost electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.\n\nThis project received funding from the Italian Ministry for University and Research (MUR) in the frame of the Next Generation EU National Recovery and Resilience Plan for the following projects: (1) PRIN2022PNRR, project P2022YYTKF─Targeting rare epileptic encephalopathies: design and preclinical development of KCNT1 modulators─TELOS to C.O., A.B., and I.G.-M.; (2) PRIN2022PNRR, project P2022FJXY5─KCNT potassium channels variants in severe epilepsies: identification of new pathogenic mechanisms and assessment of novel molecular and pharmacological strategies as precision-medicine approaches to M.V.S. and F.M.; (3) PRIN2022PNRR, project P2022ZANRF─Pharmacological targeting G protein-modulated potassium channels in a genetic model of absence epilepsy to M.T.; M.T. received funding from MUR in the frame of the Next Generation EU National Recovery and Resilience Plan, within the project “A multiscale integrated approach to the study of the nervous system in health and disease” (MNESYS), Mission 4 “Education and research”, Component 2 “From research to firms”, Investment line 1.3 “Enlarged partnerships extended to universities, research centres, enterprises and funding research projects”. The present work was also supported by MUR for the project PRIN2022, 2022M3KJ4N – Kv7 channels in pain: pathophysiological mechanisms, peripheral biomarkers, and treatment opportunities to M.T., and by the following Ricerca Finalizzata (RF) Projects from the Italian Ministry of Health (MoH): RF-2019-12370491 to M.T., and PNRR-MR1-2022-12376528 to M.T. and M.V.S., C.O. received funding from the University of Salerno (FARB2023 project ORSA238219). C.O. and M.T. also received funding from the Regione Campania, within PON FESR 2021–2027 fundings, with the project “Approcci innovativi allo studio di patogenesi, modelli, terapie e percorsi assistenziali in malattie rare neuropsichiatriche, neuromuscolari e sensoriali─NEURORARE”. NVIDIA Corporation is gratefully acknowledged for its support with the donation of the GPUs used for this research to CO.\n\nThis article references 102 other publications.\n\n1\n\nYuan, A.; Santi, C. M.; Wei, A.; Wang, Z.-W.; Pollak, K.; Nonet, M.; Kaczmarek, L.; Crowder, C. M.; Salkoff, L. The Sodium-Activated Potassium Channel Is Encoded by a Member of the Slo Gene Family. Neuron 2003, 37 (5), 765– 773, DOI: 10.1016/S0896-6273(03)00096-5\n\n2\n\nKaczmarek, L. K. Slack, Slick, and Sodium-Activated Potassium Channels. ISRN Neurosci. 2013, 2013, 354262 DOI: 10.1155/2013/354262\n\n3\n\nXu, J.; Lv, Y.-T.; Zhao, X.-Y.; Wang, J.-J.; Shen, Z.-S.; Li, J.; Zhang, F.-F.; Liu, J.; Wang, X.-H.; Xu, Y. Identification of Sodium- and Chloride-Sensitive Sites in the Slack Channel. J. Neurosci. 2023, 43 (15), 2665– 2681, DOI: 10.1523/JNEUROSCI.1365-22.2023\n\n4\n\nFranceschetti, S.; Lavazza, T.; Curia, G.; Aracri, P.; Panzica, F.; Sancini, G.; Avanzini, G.; Magistretti, J. Na+-Activated K+ Current Contributes to Postexcitatory Hyperpolarization in Neocortical Intrinsically Bursting Neurons. J. Neurophysiol. 2003, 89 (4), 2101– 2111, DOI: 10.1152/jn.00695.2002\n\n5\n\nLiu, X.; Leung, L. S. Sodium-Activated Potassium Conductance Participates in the Depolarizing Afterpotential Following a Single Action Potential in Rat Hippocampal CA1 Pyramidal Cells. Brain Res. 2004, 1023 (2), 185– 192, DOI: 10.1016/j.brainres.2004.07.017\n\n6\n\nKuret, A.; Ehinger, R.; Bischof, H.; Luczak, A.; Bausch, A.; Zhou, X.; Malli, R.; Ruth, P.; Lukowski, R. Cardioprotective Actions of the Sodium-Activated Potassium Channel Slack (aka Slo2.2, KNa1.1 or KCNT1). Eur. Heart J. 2020, 41, ehaa946.3646 DOI: 10.1093/ehjci/ehaa946.3646\n\n7\n\nYang, B.; Desai, R.; Kaczmarek, L. K. Slack and Slick KNaChannels Regulate the Accuracy of Timing of Auditory Neurons. J. Neurosci. 2007, 27 (10), 2617– 2627, DOI: 10.1523/JNEUROSCI.5308-06.2007\n\n8\n\nHuang, F.; Wang, X.; Ostertag, E. M.; Nuwal, T.; Huang, B.; Jan, Y.-N.; Basbaum, A. I.; Jan, L. Y. TMEM16C Facilitates Na+-activated K+ Currents in Rat Sensory Neurons and Regulates Pain Processing. Nat. Neurosci. 2013, 16 (9), 1284– 1290, DOI: 10.1038/nn.3468\n\n9\n\nLu, R.; Bausch, A. E.; Kallenborn-Gerhardt, W.; Stoetzer, C.; Debruin, N.; Ruth, P.; Geisslinger, G.; Leffler, A.; Lukowski, R.; Schmidtko, A. Slack Channels Expressed in Sensory Neurons Control Neuropathic Pain in Mice. J. Neurosci. 2015, 35 (3), 1125– 1135, DOI: 10.1523/JNEUROSCI.2423-14.2015\n\n10\n\nBhattacharjee, A.; Kaczmarek, L. For K Channels, Na Is the New Ca. Trends Neurosci. 2005, 28 (8), 422– 428, DOI: 10.1016/j.tins.2005.06.003\n\n11\n\nRuffin, V. A.; Gu, X. Q.; Zhou, D.; Douglas, R. M.; Sun, X.; Trouth, C. O.; Haddad, G. G. The Sodium-Activated Potassium Channel Slack Is Modulated by Hypercapnia and Acidosis. Neuroscience 2008, 151 (2), 410– 418, DOI: 10.1016/j.neuroscience.2007.10.031\n\n12\n\nHite, R. K.; MacKinnon, R. Structural Titration of Slo2.2, a Na + -Dependent K + Channel. Cell 2017, 168 (3), 390– 399.e311, DOI: 10.1016/j.cell.2016.12.030\n\n13\n\nBonardi, C. M.; Heyne, H. O.; Fiannacca, M.; Fitzgerald, M. P.; Gardella, E.; Gunning, B.; Olofsson, K.; Lesca, G.; Verbeek, N.; Stamberger, H. KCNT1-Related Epilepsies and Epileptic Encephalopathies: Phenotypic and Mutational Spectrum. Brain 2021, 144 (12), 3635– 3650, DOI: 10.1093/brain/awab219\n\n14\n\nBarcia, G.; Fleming, M. R.; Deligniere, A.; Gazula, V.-R.; Brown, M. R.; Langouet, M.; Chen, H.; Kronengold, J.; Abhyankar, A.; Cilio, R. De Novo Gain-of-Function KCNT1 Channel Mutations Cause Malignant Migrating Partial Seizures of Infancy. Nat. Genet. 2012, 44 (11), 1255– 1259, DOI: 10.1038/ng.2441\n\n15\n\nHeron, S. E.; Smith, K. R.; Bahlo, M.; Nobili, L.; Kahana, E.; Licchetta, L.; Oliver, K. L.; Mazarib, A.; Afawi, Z.; Korczyn, A. Missense Mutations in the Sodium-Gated Potassium Channel Gene KCNT1 Cause Severe Autosomal Dominant Nocturnal Frontal Lobe Epilepsy. Nat. Genet. 2012, 44 (11), 1188– 1190, DOI: 10.1038/ng.2440\n\n16\n\nRubboli, G.; Plazzi, G.; Picard, F.; Nobili, L.; Hirsch, E.; Chelly, J.; Prayson, R. A.; Boutonnat, J.; Bramerio, M.; Kahane, P. Mild Malformations of Cortical Development in Sleep-Related Hypermotor Epilepsy Due to KCNT1Mutations. Ann. Clin. Transl. Neurol. 2019, 6 (2), 386– 391, DOI: 10.1002/acn3.708\n\n17\n\nMartin, H. C.; Kim, G. E.; Pagnamenta, A. T.; Murakami, Y.; Carvill, G. L.; Meyer, E.; Copley, R. R.; Rimmer, A.; Barcia, G.; Fleming, M. R. Clinical Whole-Genome Sequencing in Severe Early-Onset Epilepsy Reveals New Genes and Improves Molecular Diagnosis. Hum. Mol. Genet. 2014, 23 (12), 3200– 3211, DOI: 10.1093/hmg/ddu030\n\n18\n\nOhba, C.; Kato, M.; Takahashi, N.; Osaka, H.; Shiihara, T.; Tohyama, J.; Nabatame, S.; Azuma, J.; Fujii, Y.; Hara, M. De Novo KCNT1Mutations in Early-Onset Epileptic Encephalopathy. Epilepsia 2015, 56 (9), e121– e128, DOI: 10.1111/epi.13072\n\n19\n\nLim, C. X.; Ricos, M. G.; Dibbens, L. M.; Heron, S. E. KCNT1Mutations in Seizure Disorders: the Phenotypic Spectrum and Functional Effects. J. Med. Genet. 2016, 53 (4), 217– 225, DOI: 10.1136/jmedgenet-2015-103508\n\n20\n\nMcTague, A.; Howell, K. B.; Cross, J. H.; Kurian, M. A.; Scheffer, I. E. The Genetic Landscape of the Epileptic Encephalopathies of Infancy and Childhood. Lancet Neurol. 2016, 15 (3), 304– 316, DOI: 10.1016/S1474-4422(15)00250-1\n\n21\n\nGururaj, S.; Palmer, E. E.; Sheehan, G. D.; Kandula, T.; Macintosh, R.; Ying, K.; Morris, P.; Tao, J.; Dias, K.-R.; Zhu, Y. A De Novo Mutation in the Sodium-Activated Potassium Channel KCNT2 Alters Ion Selectivity and Causes Epileptic Encephalopathy. Cell Rep. 2017, 21 (4), 926– 933, DOI: 10.1016/j.celrep.2017.09.088\n\n22\n\nAmbrosino, P.; Soldovieri, M. V.; Bast, T.; Turnpenny, P. D.; Uhrig, S.; Biskup, S.; Döcker, M.; Fleck, T.; Mosca, I.; Manocchio, L. De Novo Gain-of-Function Variants in KCNT2 as a Novel Cause of Developmental and Epileptic Encephalopathy. Ann. Neurol. 2018, 83 (6), 1198– 1204, DOI: 10.1002/ana.25248\n\n23\n\nCioclu, M. C.; Mosca, I.; Ambrosino, P.; Puzo, D.; Bayat, A.; Wortmann, S. B.; Koch, J.; Strehlow, V.; Shirai, K.; Matsumoto, N. KCNT2-Related Disorders: Phenotypes, Functional, and Pharmacological Properties. Ann. Neurol. 2023, 94 (2), 332– 349, DOI: 10.1002/ana.26662\n\n24\n\nRychkov, G. Y.; Shaukat, Z.; Lim, C. X.; Hussain, R.; Roberts, B. J.; Bonardi, C. M.; Rubboli, G.; Meaney, B. F.; Whitney, R.; Møller, R. S. Functional Effects of Epilepsy Associated KCNT1Mutations Suggest Pathogenesis via Aberrant Inhibitory Neuronal Activity. Int. J. Mol. Sci. 2022, 23 (23), 15133 DOI: 10.3390/ijms232315133\n\n25\n\nHinckley, C. A.; Zhu, Z.; Chu, J.; Gubbels, C.; Danker, T.; Cherry, J. J.; Whelan, C. D.; Engle, S. J.; Nguyen, V. Functional Evaluation of Epilepsy-Associated KCNT1 Variants in Multiple Cellular Systems Reveals a Predominant Gain of Function Impact on Channel Properties. Epilepsia 2023, 64 (8), 2126– 2136, DOI: 10.1111/epi.17648\n\n26\n\nKim, G. E.; Kronengold, J.; Barcia, G.; Quraishi, I. H.; Martin, H. C.; Blair, E.; Taylor, J. C.; Dulac, O.; Colleaux, L.; Nabbout, R.; Kaczmarek, L. Human Slack Potassium Channel Mutations Increase Positive Cooperativity between Individual Channels. Cell Rep. 2014, 9 (5), 1661– 1672, DOI: 10.1016/j.celrep.2014.11.015\n\n27\n\nFleming, M. R.; Brown, M. R.; Kronengold, J.; Zhang, Y.; Jenkins, D. P.; Barcia, G.; Nabbout, R.; Bausch, A. E.; Ruth, P.; Lukowski, R. Stimulation of Slack K+ Channels Alters Mass at the Plasma Membrane by Triggering Dissociation of a Phosphatase-Regulatory Complex. Cell Rep. 2016, 16 (9), 2281– 2288, DOI: 10.1016/j.celrep.2016.07.024\n\n28\n\nZhang, Y.; Brown, M. R.; Hyland, C.; Chen, Y.; Kronengold, J.; Fleming, M. R.; Kohn, A. B.; Moroz, L. L.; Kaczmarek, L. K. Regulation of Neuronal Excitability by Interaction of Fragile X Mental Retardation Protein with Slack Potassium Channels. J. Neurosci. 2012, 32 (44), 15318– 15327, DOI: 10.1523/JNEUROSCI.2162-12.2012\n\n29\n\nCole, B. A.; Clapcote, S. J.; Muench, S. P.; Lippiat, J. D. Targeting KNa1.1 Channels in KCNT1-Associated Epilepsy. Trends Pharmacol. Sci. 2021, 42 (8), 700– 713, DOI: 10.1016/j.tips.2021.05.003\n\n30\n\nMilligan, C. J.; Li, M.; Gazina, E. V.; Heron, S. E.; Nair, U.; Trager, C.; Reid, C. A.; Venkat, A.; Younkin, D. P.; Dlugos, D. J. KCNT1Gain of Function in 2 Epilepsy Phenotypes Is Reversed by Quinidine. Ann. Neurol. 2014, 75 (4), 581– 590, DOI: 10.1002/ana.24128\n\n31\n\nRizzo, F.; Ambrosino, P.; Guacci, A.; Chetta, M.; Marchese, G.; Rocco, T.; Soldovieri, M. V.; Manocchio, L.; Mosca, I.; Casara, G. Characterization of Two De Novo KCNT1Mutations in Children with Malignant Migrating Partial Seizures in Infancy. Mol. Cell. Neurosci. 2016, 72, 54– 63, DOI: 10.1016/j.mcn.2016.01.004\n\n32\n\nYang, B.; Gribkoff, V.; Pan, J.; Damagnez, V.; Dworetzky, S.; Boissard, C.; Bhattacharjee, A.; Yan, Y.; Sigworth, F.; Kaczmarek, L. Pharmacological Activation and Inhibition of Slack (Slo2.2) Channels. Neuropharmacology 2006, 51 (4), 896– 906, DOI: 10.1016/j.neuropharm.2006.06.003\n\n33\n\nFitzgerald, M. P.; Fiannacca, M.; Smith, D. M.; Gertler, T. S.; Gunning, B.; Syrbe, S.; Verbeek, N.; Stamberger, H.; Weckhuysen, S.; Ceulemans, B. Treatment Responsiveness in KCNT1-Related Epilepsy. Neurotherapeutics 2019, 16 (3), 848– 857, DOI: 10.1007/s13311-019-00739-y\n\n34\n\nDilena, R.; DiFrancesco, J. C.; Soldovieri, M. V.; Giacobbe, A.; Ambrosino, P.; Mosca, I.; Galli, M. A.; Guez, S.; Fumagalli, M.; Miceli, F. Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy. Neurotherapeutics 2018, 15 (4), 1112– 1126, DOI: 10.1007/s13311-018-0657-9\n\n35\n\nMalik, M.; Camm, A. J. Evaluation of Drug-Induced QT Interval Prolongation. Drug Saf. 2001, 24 (5), 323– 351, DOI: 10.2165/00002018-200124050-00001\n\n36\n\nMullen, S. A.; Carney, P. W.; Roten, A.; Ching, M.; Lightfoot, P. A.; Churilov, L.; Nair, U.; Li, M.; Berkovic, S. F.; Petrou, S.; Scheffer, I. E. Precision Therapy for Epilepsy due to KCNT1Mutations. Neurology 2018, 90 (1), e67– e72, DOI: 10.1212/WNL.0000000000004769\n\n37\n\nXu, D.; Chen, S.; Yang, J.; Wang, X.; Fang, Z.; Li, M. Precision Therapy with Quinidine of KCNT1-Related Epileptic Disorders: A systematic review. Br. J. Clin. Pharmacol. 2022, 88 (12), 5096– 5112, DOI: 10.1111/bcp.15479\n\n38\n\nFinlayson, K.; Witchel, H. J.; McCulloch, J.; Sharkey, J. Acquired QT Interval Prolongation and HERG: Implications for Drug Discovery and Development. Eur. J. Pharmacol. 2004, 500 (1–3), 129– 142, DOI: 10.1016/j.ejphar.2004.07.019\n\n39\n\nPo, S. S.; Wang, D. W.; Yang, I. C.-H.; Johnson, J. P.; Nie, L.; Bennett, P. B. Modulation of HERG Potassium Channels by Extracellular Magnesium and Quinidine. J. Cardiovasc. Pharmacol. 1999, 33 (2), 181– 185, DOI: 10.1097/00005344-199902000-00002\n\n40\n\nPaul, A. A.; Witchel, H. J.; Hancox, J. C. Inhibition of the Current of Heterologously Expressed HERG Potassium Channels by Flecainide and Comparison with Quinidine, Propafenone and Lignocaine. Br. J. Pharmacol. 2002, 136 (5), 717– 729, DOI: 10.1038/sj.bjp.0704784\n\n41\n\nKlaerke, D. A.; Tejada, M.; Stolpe; Meinild Clofilium Inhibits Slick and Slack Potassium Channels. Biol.: Targets Ther. 2012, 6, 465– 470, DOI: 10.2147/BTT.S33827\n\n42\n\nSpitznagel, B. D.; Mishra, N. M.; Qunies, A. a. M.; Prael, F. J.; Du, Y.; Kozek, K. A.; Lazarenko, R. M.; Denton, J. S.; Emmitte, K. A.; Weaver, C. D. VU0606170, a Selective Slack Channels Inhibitor, Decreases Calcium Oscillations in Cultured Cortical Neurons. ACS Chem. Neurosci. 2020, 11 (21), 3658– 3671, DOI: 10.1021/acschemneuro.0c00583\n\n43\n\nGriffin, A. M.; Kahlig, K. M.; Hatch, R. J.; Hughes, Z. A.; Chapman, M. L.; Antonio, B.; Marron, B. E.; Wittmann, M.; Martinez-Botella, G. Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series. ACS Med. Chem. Lett. 2021, 12 (4), 593– 602, DOI: 10.1021/acsmedchemlett.0c00675\n\n44\n\nCole, B. A.; Johnson, R. M.; Dejakaisaya, H.; Pilati, N.; Fishwick, C. W. G.; Muench, S. P.; Lippiat, J. D. Structure-Based Identification and Characterization of Inhibitors of the Epilepsy-Associated KNa1.1 (KCNT1) Potassium Channel. iScience 2020, 23 (5), 101100 DOI: 10.1016/j.isci.2020.101100\n\n45\n\nQunies, A. M.; Emmitte, K. A. Small-Molecule Inhibitors of Slack Potassium Channels as Potential Therapeutics for Childhood Epilepsies. Pharm. Pat. Anal. 2022, 11 (2), 45– 56, DOI: 10.4155/ppa-2022-0002\n\n46\n\nQunies, A. M.; Spitznagel, B. D.; Du, Y.; Weaver, C. D.; Emmitte, K. A. Design, synthesis, and biological evaluation of a novel series of 1,2,4-oxadiazole inhibitors of SLACK potassium channels: Identification of in vitro tool VU0935685. Bioorg. Med. Chem. 2023, 95, 117487 DOI: 10.1016/j.bmc.2023.117487\n\n47\n\nMcTague, A.; Nair, U.; Malhotra, S.; Meyer, E.; Trump, N.; Gazina, E. V.; Papandreou, A.; Ngoh, A.; Ackermann, S.; Ambegaonkar, G. Clinical and Molecular Characterization of KCNT1-Related Severe Early-Onset Epilepsy. Neurology 2018, 90 (1), e55– e66, DOI: 10.1212/WNL.0000000000004762\n\n48\n\nSchrödinger Release 2022–3: Prime; Schoredinger LLC: New York, 2023.\n\n49\n\nGioia, D.; Bertazzo, M.; Recanatini, M.; Masetti, M.; Cavalli, A. Dynamic Docking: A Paradigm Shift in Computational Drug Discovery. Molecules 2017, 22 (11), 2029 DOI: 10.3390/molecules22112029\n\n50\n\nDi Sarno, V.; Giovannelli, P.; Medina-Peris, A.; Ciaglia, T.; Di Donato, M.; Musella, S.; Lauro, G.; Vestuto, V.; Smaldone, G.; Di Matteo, F. New TRPM8 Blockers Exert Anticancer Activity over Castration-Resistant Prostate Cancer Models. Eur. J. Med. Chem. 2022, 238, 114435 DOI: 10.1016/j.ejmech.2022.114435\n\n51\n\nOstacolo, C.; Miceli, F.; Di Sarno, V.; Nappi, P.; Iraci, N.; Soldovieri, M. V.; Ciaglia, T.; Ambrosino, P.; Vestuto, V.; Lauritano, A. Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators. J. Med. Chem. 2020, 63 (1), 163– 185, DOI: 10.1021/acs.jmedchem.9b00796\n\n52\n\nMusella, S.; Carotenuto, L.; Iraci, N.; Baroli, G.; Ciaglia, T.; Nappi, P.; Basilicata, M. G.; Salviati, E.; Barrese, V.; Vestuto, V. Beyond Retigabine: Design, Synthesis, and Pharmacological Characterization of a Potent and Chemically Stable Neuronal Kv7 Channel Activator with Anticonvulsant Activity. J. Med. Chem. 2022, 65 (16), 11340– 11364, DOI: 10.1021/acs.jmedchem.2c00911\n\n53\n\nCerqua, I.; Musella, S.; Peltner, L. K.; D’Avino, D.; Di Sarno, V.; Granato, E.; Vestuto, V.; Di Matteo, R.; Pace, S.; Ciaglia, T. Discovery and Optimization of Indoline-Based Compounds as Dual 5-LOX/sEH Inhibitors: In Vitro and In Vivo Anti-Inflammatory Characterization. J. Med. Chem. 2022, 65 (21), 14456– 14480, DOI: 10.1021/acs.jmedchem.2c00817\n\n54\n\nBertamino, A.; Iraci, N.; Ostacolo, C.; Ambrosino, P.; Musella, S.; Di Sarno, V.; Ciaglia, T.; Pepe, G.; Sala, M.; Soldovieri, M. V. Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic Activity. J. Med. Chem. 2018, 61 (14), 6140– 6152, DOI: 10.1021/acs.jmedchem.8b00545\n\n55\n\nBertamino, A.; Ostacolo, C.; Ambrosino, P.; Musella, S.; Di Sarno, V.; Ciaglia, T.; Soldovieri, M. V.; Iraci, N.; Fernandez Carvajal, A.; de la Torre-Martinez, R. Tryptamine-Based Derivatives as Transient Receptor Potential Melastatin Type 8 (TRPM8) Channel Modulators. J. Med. Chem. 2016, 59 (5), 2179– 2191, DOI: 10.1021/acs.jmedchem.5b01914\n\n56\n\nOstacolo, C.; Di Sarno, V.; Lauro, G.; Pepe, G.; Musella, S.; Ciaglia, T.; Vestuto, V.; Autore, G.; Bifulco, G.; Marzocco, S. Identification of an Indol-Based Multi-Target Kinase Inhibitor through Phenotype Screening and Target Fishing Using Inverse Virtual Screening Approach. Eur. J. Med. Chem. 2019, 167, 61– 75, DOI: 10.1016/j.ejmech.2019.01.066\n\n57\n\nGomez-Monterrey, I.; Bertamino, A.; Porta, A.; Carotenuto, A.; Musella, S.; Aquino, C.; Granata, I.; Sala, M.; Brancaccio, D.; Picone, D. Identification of the Spiro(oxindole-3,3′-thiazolidine)-Based Derivatives as Potential p53 Activity Modulators. J. Med. Chem. 2010, 53 (23), 8319– 8329, DOI: 10.1021/jm100838z\n\n58\n\nOstacolo, C.; Di Sarno, V.; Musella, S.; Ciaglia, T.; Vestuto, V.; Pepe, G.; Merciai, F.; Campiglia, P.; Monterrey, I. M. G.; Bertamino, A. An Efficient Approach to Aromatic Aminomethylation Using Dichloromethane as Methylene Source. Front. Chem. 2019, 7, 568 DOI: 10.3389/fchem.2019.00568\n\n59\n\nBeacham, D. W.; Blackmer, T.; O’ Grady, M.; Hanson, G. T. Cell-Based Potassium Ion Channel Screening Using the FluxOR Assay. SLAS Discovery 2010, 15 (4), 441– 446, DOI: 10.1177/1087057109359807\n\n60\n\nBiton, B.; Sethuramanujam, S.; Picchione, K. E.; Bhattacharjee, A.; Khessibi, N.; Chesney, F.; Lanneau, C.; Curet, O.; Avenet, P. The Antipsychotic Drug Loxapine Is an Opener of the Sodium-Activated Potassium Channel Slack (Slo2.2). J. Pharmacol. Exp. Ther. 2012, 340 (3), 706– 715, DOI: 10.1124/jpet.111.184622\n\n61\n\nZhang, J.-H.; Chung, T. D. Y.; Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. SLAS Discovery 1999, 4 (2), 67– 73, DOI: 10.1177/108705719900400206\n\n62\n\nZhang, J.; Liu, S.; Fan, J.; Yan, R.; Huang, B.; Zhou, F.; Yuan, T.; Gong, J.; Huang, Z.; Jiang, D. Structural Basis of Human Slo2.2 Channel Gating and Modulation. Cell Rep. 2023, 42 (8), 112858 DOI: 10.1016/j.celrep.2023.112858\n\n63\n\nRoss, D. L.; Cooper, M. J.; Koo, C. C.; Skinner, M. P.; Davis, L. M.; Richards, D. A.; Uther, J. B. Proarrhythmic Effects of Antiarrhythmic Drugs. Med. J. Aust. 1990, 153 (1), 37– 47, DOI: 10.5694/j.1326-5377.1990.tb125462.x\n\n64\n\nTaglialatela, M.; Castaldo, P.; Pannaccione, A.; Giorgio, G.; Annunziato, L. Human Ether-a-gogo Related Gene (HERG) K Channels as Pharmacological Targets. Biochem. Pharmacol. 1998, 55 (11), 1741– 1746, DOI: 10.1016/S0006-2952(98)00002-1\n\n65\n\nAronov, A. M. Common Pharmacophores for Uncharged Human Ether-a-go-go-Related Gene (hERG) Blockers. J. Med. Chem. 2006, 49 (23), 6917– 6921, DOI: 10.1021/jm060500o\n\n66\n\nBains, W.; Basman, A.; White, C. HERG Binding Specificity and Binding Site Structure: Evidence from a Fragment-Based Evolutionary Computing SAR Study. Prog. Biophys. Mol. Biol. 2004, 86 (2), 205– 233, DOI: 10.1016/j.pbiomolbio.2003.09.001\n\n67\n\nDown, K.; Amour, A.; Baldwin, I. R.; Cooper, A. W. J.; Deakin, A. M.; Felton, L. M.; Guntrip, S. B.; Hardy, C.; Harrison, Z. A.; Jones, K. L. Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease. J. Med. Chem. 2015, 58 (18), 7381– 7399, DOI: 10.1021/acs.jmedchem.5b00767\n\n68\n\nYamakawa, Y.; Furutani, K.; Inanobe, A.; Ohno, Y.; Kurachi, Y. Pharmacophore Modeling for hERG Channel Facilitation. Biochem. Biophys. Res. Commun. 2012, 418 (1), 161– 166, DOI: 10.1016/j.bbrc.2011.12.153\n\n69\n\nCavalli, A.; Poluzzi, E.; De Ponti, F.; Recanatini, M. Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome: Insights from a CoMFA Study of HERG K+ Channel Blockers. J. Med. Chem. 2002, 45 (18), 3844– 3853, DOI: 10.1021/jm0208875\n\n70\n\nStoyanova-Slavova, I. B.; Slavov, S. H.; Buzatu, D. A.; Beger, R. D.; Wilkes, J. G. 3D-SDAR Modeling of hERG Potassium Channel Affinity: A Case Study in Model Design and Toxicophore Identification. J. Mol. Graphics Modell. 2017, 72, 246– 255, DOI: 10.1016/j.jmgm.2017.01.012\n\n71\n\nCavalli, A.; Buonfiglio, R.; Ianni, C.; Masetti, M.; Ceccarini, L.; Caves, R.; Chang, M. W. Y.; Mitcheson, J. S.; Roberti, M.; Recanatini, M. Computational Design and Discovery of “Minimally Structured” hERG Blockers. J. Med. Chem. 2012, 55 (8), 4010– 4014, DOI: 10.1021/jm201194q\n\n72\n\nBochevarov, A. D.; Harder, E.; Hughes, T. F.; Greenwood, J. R.; Braden, D. A.; Philipp, D. M.; Rinaldo, D.; Halls, M. D.; Zhang, J.; Friesner, R. A. Jaguar: A High-Performance Quantum Chemistry Software Program with Strengths in Life and Materials Sciences. Int. J. Quantum Chem. 2013, 113 (18), 2110– 2142, DOI: 10.1002/qua.24481\n\n73\n\nSoldovieri, M. V.; Miceli, F.; Taglialatela, M. Driving With No Brakes: Molecular Pathophysiology of Kv7 Potassium Channels. Physiology 2011, 26 (5), 365– 376, DOI: 10.1152/physiol.00009.2011\n\n74\n\nNappi, P.; Miceli, F.; Soldovieri, M. V.; Ambrosino, P.; Barrese, V.; Taglialatela, M. Epileptic channelopathies caused by neuronal Kv7 (KCNQ) channel dysfunction. Pflügers Arch. - Eur. J. Physiol. 2020, 472 (7), 881– 898, DOI: 10.1007/s00424-020-02404-2\n\n75\n\nTaglialatela, M.; Barrese, V.; Miceli; Soldovieri, M.; Ambrosino, P.; Iannotti, F.; Cilio, R. Neuronal Potassium Channel Openers in the Management of Epilepsy: Role and Potential of Retigabine. Clin. Pharmacol.: Adv. Appl. 2010, 2, 225– 236, DOI: 10.2147/CPAA.S15369\n\n76\n\nMiceli, F.; Soldovieri, M. V.; Martire, M.; Taglialatela, M. Molecular Pharmacology and Therapeutic Potential of Neuronal Kv7-Modulating Drugs. Curr. Opin. Pharmacol. 2008, 8 (1), 65– 74, DOI: 10.1016/j.coph.2007.10.003\n\n77\n\nPang, K. S.; Han, Y. R.; Noh, K.; Lee, P. I.; Rowland, M. Hepatic Clearance Concepts and Misconceptions: Why the Well-Stirred Model is Still Used Even Though it is not Physiologic Reality?. Biochem. Pharmacol. 2019, 169, 113596 DOI: 10.1016/j.bcp.2019.07.025\n\n78\n\nMcNaney, C. A.; Drexler, D. M.; Hnatyshyn, S. Y.; Zvyaga, T. A.; Knipe, J. O.; Belcastro, J. V.; Sanders, M. An Automated Liquid Chromatography-Mass Spectrometry Process to Determine Metabolic Stability Half-Life and Intrinsic Clearance of Drug Candidates by Substrate Depletion. Assay Drug Dev. Technol. 2008, 6 (1), 121– 129, DOI: 10.1089/adt.2007.103\n\n79\n\nIshii, A.; Shioda, M.; Okumura, A.; Kidokoro, H.; Sakauchi, M.; Shimada, S.; Shimizu, T.; Osawa, M.; Hirose, S.; Yamamoto, T. A Rrecurrent KCNT1Mutation in two Sporadic Cases with Malignant Migrating Partial Seizures in Infancy. Gene 2013, 531 (2), 467– 471, DOI: 10.1016/j.gene.2013.08.096\n\n80\n\nMikati, M. A.; Jiang, Y.; Carboni, M.; Shashi, V.; Petrovski, S.; Spillmann, R.; Milligan, C. J.; Li, M.; Grefe, A.; McConkie, A. Quinidine in the Treatment of KCNT1-Positive Epilepsies. Ann. Neurol. 2015, 78 (6), 995– 999, DOI: 10.1002/ana.24520\n\n81\n\nBateman, A.; Martin, M.-J.; Orchard, S.; Magrane, M.; Ahmad, S.; Alpi, E.; Bowler-Barnett, E. H.; Britto, R.; Bye-A-Jee, H.; Cukura, A. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 2023, 51 (D1), D523– D531, DOI: 10.1093/nar/gkac1052\n\n82\n\nThompson, J. D.; Higgins, D. G.; Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22 (22), 4673– 4680, DOI: 10.1093/nar/22.22.4673\n\n83\n\nJacobson, M. P.; Pincus, D. L.; Rapp, C. S.; Day, T. J. F.; Honig, B.; Shaw, D. E.; Friesner, R. A. A Hierarchical Approach to All-Atom Protein Loop Prediction. Proteins: Struct., Funct., Bioinf. 2004, 55 (2), 351– 367, DOI: 10.1002/prot.10613\n\n84\n\nJacobson, M. P.; Friesner, R. A.; Xiang, Z.; Honig, B. On the Role of the Crystal Environment in Determining Protein Side-chain Conformations. J. Mol. Biol. 2002, 320 (3), 597– 608, DOI: 10.1016/S0022-2836(02)00470-9\n\n85\n\nMadhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and Ligand Preparation: Parameters, Protocols, and Influence on Virtual Screening Enrichments. J. Comput.-Aided Mol. Des. 2013, 27 (3), 221– 234, DOI: 10.1007/s10822-013-9644-8\n\n86\n\nKim, S.; Chen, J.; Cheng, T.; Gindulyte, A.; He, J.; He, S.; Li, Q.; Shoemaker, B. A.; Thiessen, P. A.; Yu, B. PubChem 2023 update. Nucleic Acids Res. 2023, 51 (D1), D1373– D1380, DOI: 10.1093/nar/gkac956\n\n87\n\nSchrödinger Release 2019–1: LigPrep; Schrödinger, LLC: New York, NY, 2019.\n\n88\n\nBowers, K. J.; Chow, D. E.; Xu, H.; Dror, R. O.; Eastwood, M. P.; Gregersen, B. A.; Klepeis, J. L.; Kolossvary, I.; Moraes, M. A.; Sacerdoti, F. D. In Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters, ACM/IEEE SC 2006 Conference (SC’06); IEEE, 2006.\n\n89\n\nLomize, M. A.; Pogozheva, I. D.; Joo, H.; Mosberg, H. I.; Lomize, A. L. OPM Database and PPM Web Server: Resources for Positioning of Proteins in Membranes. Nucleic Acids Res. 2012, 40 (D1), D370– D376, DOI: 10.1093/nar/gkr703\n\n90\n\nJorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of Simple Potential Functions for Simulating Liquid Water. J. Chem. Phys. 1983, 79 (2), 926– 935, DOI: 10.1063/1.445869\n\n91\n\nJorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. J. Am. Chem. Soc. 1996, 118 (45), 11225– 11236, DOI: 10.1021/ja9621760\n\n92\n\nBarreca, M. L.; Iraci, N.; Manfroni, G.; Gaetani, R.; Guercini, C.; Sabatini, S.; Tabarrini, O.; Cecchetti, V. Accounting for Target Flexibility and Water Molecules by Docking to Ensembles of Target Structures: The HCV NS5B Palm Site I Inhibitors Case Study. J. Chem. Inf. Model. 2014, 54 (2), 481– 497, DOI: 10.1021/ci400367m\n\n93\n\nAstolfi, A.; Iraci, N.; Sabatini, S.; Barreca, M.; Cecchetti, V. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening. Molecules 2015, 20 (9), 15842– 15861, DOI: 10.3390/molecules200915842\n\n94\n\nFriesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J. Med. Chem. 2004, 47 (7), 1739– 1749, DOI: 10.1021/jm0306430\n\n95\n\nHalgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. J. Med. Chem. 2004, 47 (7), 1750– 1759, DOI: 10.1021/jm030644s\n\n96\n\nFriesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein–Ligand Complexes. J. Med. Chem. 2006, 49 (21), 6177– 6196, DOI: 10.1021/jm051256o\n\n97\n\nDuan, J.; Dixon, S. L.; Lowrie, J. F.; Sherman, W. Analysis and Comparison of 2D Fingerprints: Insights Into Database Screening Performance Using eight Fingerprint Methods. J. Mol. Graphics Modell. 2010, 29 (2), 157– 170, DOI: 10.1016/j.jmgm.2010.05.008\n\n98\n\nSastry, M.; Lowrie, J. F.; Dixon, S. L.; Sherman, W. Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments. J. Chem. Inf. Model. 2010, 50 (5), 771– 784, DOI: 10.1021/ci100062n\n\n99\n\nSherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R. Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects. J. Med. Chem. 2006, 49, 534– 553, DOI: 10.1021/jm050540c\n\n100\n\nAmbrosino, P.; Soldovieri, M. V.; De Maria, M.; Russo, C.; Taglialatela, M. Functional and Biochemical Interaction Between PPARα Receptors and TRPV1 Channels: Potential Role in PPARα Agonists-Mediated Analgesia. Pharmacol. Res. 2014, 87, 113– 122, DOI: 10.1016/j.phrs.2014.06.015\n\n101\n\nMiceli, F.; Soldovieri, M. V.; Ambrosino, P.; De Maria, M.; Migliore, M.; Migliore, R.; Taglialatela, M. Early-Onset Epileptic Encephalopathy Caused by Gain-of-Function Mutations in the Voltage Sensor of Kv7.2 and Kv7.3 Potassium Channel Subunits. J. Neurosci. 2015, 35 (9), 3782– 3793, DOI: 10.1523/JNEUROSCI.4423-14.2015\n\n102\n\nChen, Y.; Zhu, F.; Hammill, J.; Holbrook, G.; Yang, L.; Freeman, B.; White, K. L.; Shackleford, D. M.; O’Loughlin, K. G.; Charman, S. A. Selecting an Anti-Malarial Clinical Candidate from two Potent Dihydroisoquinolones. Malar. J. 2021, 20 (1), 107 DOI: 10.1186/s12936-021-03617-1"
    }
}